| Authors: |
Goldberg FW; Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K., Finlay MRV; Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K., Ting AKT; Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K., Beattie D; Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K., Lamont GM; Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K., Fallan C; Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K., Wrigley GL; Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K., Schimpl M; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0FZ, U.K., Howard MR; Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K., Williamson B; Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K., Vazquez-Chantada M; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0FZ, U.K., Barratt DG; Discovery Sciences, R&D, AstraZeneca, Cambridge CB4 0FZ, U.K., Davies BR; Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K., Cadogan EB; Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K., Ramos-Montoya A; Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K., Dean E; Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K. |